EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases

Alec Sevilla iD, James Grichnik

Experimental Dermatology · 2024

DOI: 10.1111/exd.15091 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Alec Sevilla und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, New York Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Stem Cell Factor, Melanocytes, Mast Cells, Mastocytosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 200 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KIT ligand and its associated receptor KIT serve as a master regulatory system for both melanocytes and mast cells controlling survival, migration, proliferation and activation. Blockade of this pathway results in cell depletion, while overactivation leads to mastocytosis or melanoma. Expression defects are associated with pigmentary and mast cell disorders. KIT ligand regulation is complex but efficient targeting of this system would be of significant benefit to those suffering from melanocytic or mast cell disorders. Herein, we review the known associations of this pathway with cutaneous diseases and the regulators of this system both in skin and in the more well‐studied germ cell system. Exogenous agents modulating this pathway will also be presented. Ultimately, we will review potential therapeutic opportunities to help our patients with melanocytic and mast cell disease processes potentially including vitiligo, hair greying, melasma, urticaria, mastocytosis and melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stem Cell FactorMelanocytesMast CellsMastocytosisProto-Oncogene Proteins c-kitHumansMelanomaVitiligoPigmentation DisordersSkin NeoplasmsAnimals

Stichwörter der Autor:innen

KITKIT ligandmast cellsmelanocytespigmentation

Substanzen

Stem Cell FactorProto-Oncogene Proteins c-kitKIT protein, human

Autor:innen und Institutionen

  • Department of Dermatology, New York Medical College, New York, New York, USA.
  • Department of Internal Medicine, Lakeland Regional Health, Lakeland, Florida, USA.
  • Department of Dermatology and Cutaneous Surgery, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.

ORCID-Profile: Alec Sevilla

Zitieren

APA

Sevilla, A., & Grichnik, J. (2024). Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology. https://doi.org/10.1111/exd.15091

Vancouver

Sevilla A, Grichnik J. Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases. Experimental Dermatology. 2024. doi:10.1111/exd.15091

BibTeX
@article{Sevilla2024,
  author = {Sevilla, Alec and Grichnik, James},
  title = {Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.15091}
}
Kostenlos starten →